Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4910145 | 0.98 | TAAR1 (0.58) | TAAR1ATMTMEM97SIGMAR1LOXL2 | |
| SCHEMBL708919 | 0.86 | MEN1 (0.61) | TAAR1ATMTMEM97SIGMAR1LOXL2 | |
| SCHEMBL16373707 | 0.85 | L3MBTL1 (0.64) | TAAR1ATMTMEM97SIGMAR1LOXL2 | |
| SCHEMBL10156581 | 0.82 | TAAR1 (0.76) | TAAR1ATMTMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL7360165 | 0.80 | LOXL2 (0.54) | SIGMAR1LOXL2ALDH1A1NPC1RAB9A | |
| SCHEMBL22048586 | 0.78 | LOXL2 (0.52) | LOXL2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5429971 | 0.77 | ALDH1A1 (0.51) | LOXL2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| Dimethylamine SCHEMBL11263225 | 0.76 | LMNA (0.54) | LOXL2ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1488487 | 0.76 | LOXL2 (0.50) | LOXL2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14824989 | 0.76 | LOXL2 (0.50) | LOXL2ALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158564-A1 | QUATERNARY AMMONIUM-FUNCTIONALIZED POLYMERS AND METHODS OF MAKING AND USING SAME | U.S. DEPARTMENT OF ENERGY | 2024-05-16 | — | — | US | claimed |
| WO-2022159848-A1 | QUATERNARY AMMONIUM-FUNCTIONALIZED POLYMERS AND METHODS OF MAKING AND USING SAME | CORNELL UNIVERSITY (US) | 2022-07-28 | — | — | WO | claimed |
| EP-2049536-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-22 | — | — | EP | claimed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | claimed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | claimed |
| WO-2008011521-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| CN-1440401-A | Amino substituted dibenzothiophene derivatives for treatmnt of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2003-09-03 | — | — | CN | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| US-4188391-A | 4-[4-(Substituted)piperidino]quinazoline cardiac stimulants | PFIZER INC. (US) | 1980-02-12 | — | — | US | disclosed |
| US-4159332-A | Prevention of or reduction in severity of myocardial infarction | UNIMED, INC. (US) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | TAAR1 4385/4885ATM 2354/4885TMEM97 2465/4885 |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | EIF2AK2, ZC3HAV1, MAVS | TAAR1 4560/4885ATM 4115/4885TMEM97 3719/4885 |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | TAAR1 4208/4885ATM 4213/4885TMEM97 3701/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | TAAR1 104/4885ATM 4091/4885TMEM97 968/4885 |
| US-20240158564-A1 | QUATERNARY AMMONIUM-FUNCTIONALIZED POLYMERS AND METHODS OF MAKING AND USING SAME | ALKBH3, ABHD10, ALKBH2 | TAAR1 1162/4885ATM 2701/4885TMEM97 2565/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | TAAR1 4571/4885ATM 3347/4885TMEM97 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.